Literature DB >> 27200642

The Cost-Effectiveness OF Canagliflozin (Cana) Versus Dapagliflozin (Dapa) In Patients With Type 2 Diabetes Mellitus (T2dm) With Inadequate Control On Metformin (Met) Monotherapy In The United Kingdom.

M Schroeder1, P Johansen2, G Thompson1, M Willis3, C Neslusan4.   

Abstract

Entities:  

Year:  2014        PMID： 27200642     DOI： 10.1016/j.jval.2014.08.694

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  4 in total

Review 1.  Canagliflozin: A Review in Type 2 Diabetes.

Authors:  Emma D Deeks; André J Scheen
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 2.  Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.

Authors:  Thomas Karagiannis; Eleni Bekiari; Apostolos Tsapas
Journal:  Core Evid       Date:  2017-03-15

Review 3.  Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK.

Authors:  S C Bain; A Bakhai; M Evans; A Green; I Menown; W D Strain
Journal:  Diabet Med       Date:  2019-07-17       Impact factor: 4.359

4.  Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.

Authors:  Cheryl Neslusan; Anna Teschemaker; Michael Willis; Pierre Johansen; Lien Vo
Journal:  Diabetes Ther       Date:  2018-02-06       Impact factor: 2.945
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.